Simplicity is a virtue.

From Washington DC,

• The House of Representatives remains in session through July 1 for floor voting and Committee business. The Senate left Capitol Hill last Thursday and will not return until July 13.

• MedCity News reports,
  • “A group of Democratic senators introduced a new bill on Thursday that would create a $5,000 cap on out-of-pocket costs for traditional Medicare beneficiaries.
  • “The Medicare Cost Cap Act was introduced by Senator Lisa Blunt Rochester (D-Delaware), Senate Finance Committee Ranking Member Ron Wyden (D-Oregon) and Senate Democratic Leader Chuck Schumer (D-New York).
  • “The bill seeks to “level the playing field” between traditional Medicare and Medicare Advantage, which has annual out-of-pocket spending caps (as do employer-sponsored insurance and coverage bought on the marketplace).” 

• The Washington Examiner relates,
  • “The [U.S.] Supreme Court will issue opinions in the eight remaining cases pending for this term this week, continuing its tradition of saving the biggest cases for the final days of its term.
  • “While the Supreme Court has released opinions in 50 of the 58 cases it heard arguments in between October 2025 and the end of April, the most highly anticipated and closely watched cases are set to be released on one of the likely two final opinion days of the term. The rulings in cases about President Donald Trump’s firing ability, along with his executive order on birthright citizenship and other disputes over biological males in women’s sports, will conclude the term.”

• Healio notes,
  • “It has been nearly a year since the U.S. Preventive Services Task Force released new recommendations, and experts remain concerned about its future.
  • “HHS removed the chair and vice chair of USPSTF last month, which came after three task force meetings were canceled under HHS Secretary Robert F. Kennedy Jr.’s tenure.

From the judicial front,

• Healthcare Finance reports,
  • “CareFirst of Maryland has filed a federal racketeering lawsuit against two former Maryland insurance brokers, alleging they used fake residences, false identities and an international referral network to enroll out-of-state and overseas clients in CareFirst health plans reserved for Maryland residents.
  • “The complaint, filed June 15 in the U.S. District Court for the District of Maryland, names Avraham Rappaport, a former licensed insurance broker based in Olney, Maryland, and his brother Eliezer Rappaport, a financial advisor and former licensed broker. It also names John Does 1-20 as alleged co-conspirators.
  • “CareFirst described itself in the filing as the victim of a “health insurance fraud conspiracy of breathtaking scale and audacity.” The insurer alleges the brothers coordinated an “international insurance-fraud machine” that allowed people who did not live in Maryland to obtain coverage through CareFirst policies intended for state residents.”

From the public health and medical / Rx research front,

• NPR lets us know “8 things to know about the gut microbiome and keeping yours healthy.”

• Health Day reports,
  • “A next-generation blood test could improve early detection of the most dangerous forms of prostate cancer.
  • “The major challenge in prostate cancer screening is not just to find more cancer cases, but to identify the cancers that are truly dangerous,” said first author Thorgerdur Palsdottir, a researcher at the Karolinska Institute in Stockholm. 
  • “Our results show that Stockholm3 identifies significantly more aggressive cancer cases than PSA [prostate-specific antigen], without increasing the number of unnecessary follow-ups,” she added in a news release.” * * *
  • “Unlike the standard PSA test, which measures a single blood protein, the Stockholm3 test combines multiple protein and genetic markers with factors like age and family history to better assess the risk of aggressive prostate cancer.
  • “The study — published June 23 in the Annals of Internal Medicine — showed that Stockholm3 detected 90% of prostate cancers, compared with 74% for PSA, without subjecting more men to unnecessary testing.”

• Medscape relates,
  • GLP-1 receptor agonists (GLP-1 RAs) are associated with reduced incidence of breast cancer among women with overweight or obesity, according to two observational studies.
  • One found that GLP-1 RA users had a roughly 30% lower incidence of breast cancer than was seen in matched nonusers. The smaller of the two, which followed more than 80,000 women at high risk for breast cancer, found a more modest 16% reduction.
  • Using GLP-1 drugs to prevent cancer is “an exciting new frontier that will likely revolutionize the field of oncology, but like any new exciting therapy we need [randomized] clinical trials to understand how to optimally” use them, said Neil M. Iyengar, MD, a breast medical oncologist who was not involved in either study.

• Cardiovascular Business tells us,
  • “Transcatheter aortic valve replacement (TAVR) is associated with certain early benefits for women not seen with surgical aortic valve replacement (SAVR), according to a new meta-analysis published in JACC: Advances.[1] These benefits were primarily seen in intermediate- and high-risk patients—and they weren’t seen at all when treating men.
  • “As TAVR expands to younger and lower-risk populations, clarifying sex-specific and time-dependent outcomes is critical for individualized valve selection,” wrote first author Hendrianus Hendrianus, MD, a researcher with Chung-Ang University in South Korea, and colleagues.
  • “The group explored data from nine different randomized controlled trials (RCTs) comparing TAVR and SAVR. Studies were required to include sex-stratified outcomes to be counted as part of this meta-analysis. The nine RCTs included more than 9,500 patients with severe aortic stenosis who were randomized to undergo TAVR or SAVR. Approximately 44% of all patients were women. The primary outcomes for these trials were slightly different from one another, but they all included all-cause mortality as a key component.
  • “After one year, TAVR was linked to a 33% relative reduction in the risk of the trial-defined endpoint for women. This was largely driven by improvements for intermediate- and high-risk patients. This trend was not seen in men.” 

From the U.S. healthcare business and artificial intelligence front,

• BioPharma Dive reports,
  • “A surge in licensing deals involving drugs from Chinese pharmaceutical firms has triggered alarms in U.S. biotech circles, setting off arguments over what it means for national security and market competition.
  • “Nearly 100 agreements between Chinese and U.S. biotechnology firms have been publicly announced since the start of 2025, according to BioPharma Dive data. Lawmakers on Capitol Hill have signaled intentions to try and disincentivize those investments. Among recent efforts are a push to add the biotechnology sector to the list of industries where investments in China will be scrutinized by U.S. regulators.
  • “The issue featured prominently [last] week at the annual meeting of the Biotechnology Innovation Organization, the industry’s top lobbying group. Multiple panels were geared towards the way licensing deals are affecting the business development landscape and early venture investment. And during a brief meeting with reporters, BIO CEO John Crowley acknowledged the tough spot the U.S. biotech ecosystem is in as well as the pros and cons of Congressional intervention.
  • “Protecting U.S. biotech is a “national security imperative,” and “we need to maintain our lead here,” he said.”  

• Fierce Healthcare offers a ranked list of the most expensive EHR projects underway in 2026, and relates,
  • “Innovaccer and Amazon Web Services (AWS) signed a multi-year strategic collaboration agreement to help health systems and payers deploy agentic AI solutions at scale. 
  • ‘The collaboration aims to bridge the gap between working AI pilots and deployments that meet security, compliance and scale requirements. Under the agreement, Innovaccer will scale agentic AI workloads using AWS services while expanding its go-to-market through the AWS marketplace.
  • “Innovaccer CEO and co-founder Abhinav Shashank said in a statement AI in healthcare, “has a production problem, not an innovation problem.”
  • “The organizations we work with are not short on ambition,” Shashank said. “What they need is the infrastructure to run AI agents reliably, securely, and at the scale their operations demand. AWS gives us exactly that, and what we bring is a decade of healthcare-native context that makes those agents actually work in the environments health systems and payers operate in every day. This agreement is about closing the gap between what AI can do for healthcare and what healthcare is currently getting from it.”
  • The collaboration also includes co-investment in customer success programs, the companies say.”

• Health Day tells us,
  • “People are becoming more comfortable communicating with their doctor through clinics’ patient portals.
  • “Folks use the portals to ask their doc questions and even to review the results of recent medical tests.
  • “But there are some matters that still require a face-to-face interaction between doctor and patient, a new study says.
  • “In all, 3 of 4 patients want to hear about a cancer diagnosis directly from their doctor, rather than through a portal message or report, researchers reported June 24 in JAMA Network Open.
  • “While most patients in the general population appreciate rapid electronic access to test results, the situation for patients with cancer is much more nuanced,” lead researcher Dr. Sheena Bhalla said in a news release. She’s a medical oncologist at the Harold C. Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center in Dallas.”

• Per Medical Economics,
  • “People enjoy healthier lives when their physicians work with community partnerships, sharing the goal of improving social and behavioral factors that treat or worsen chronic disease.
  • “Using Community Partnerships to Inform the Prevention Strategy of the Center for Medicare and Medicaid Innovation” is a new consensus study report published this spring by the National Academies of Sciences, Engineering, and Medicine. Its Standing Committee on Primary Care drafted it as a detailed road map for building effective partnerships between physicians’ practices, health care organizations, and community organizations. The committee examined what makes these partnerships work, where they fail, and what the federal government should do to fund and sustain them at scale. Drawing on real-world models from Massachusetts to Alaska, it delivers three concrete recommendations for the Centers for Medicare & Medicaid Services.
  • “This slideshow summarizes the report’s key findings. All data points come from the report, which is available free online.”